CA
NZ
UK
AU
IND
US
Roche is a Basel-based healthcare company founded in 1896 that operates through two divisions. Pharmaceuticals focuses on oncology, neurology, immunology, hemophilia, ophthalmology and other areas, while Diagnostics is a global leader in in-vitro diagnostics, offering lab tests, instruments, reagents and digital solutions. The group …
Seaport, based in Boston and founded in 2024, is a clinical-stage biopharmaceutical company developing oral treatments for depression, anxiety and other neuropsychiatric disorders. Its Glyph platform is designed to bypass first-pass liver metabolism, which may improve bioavailability and reduce liver-related side effects. The company …
Stereotaxis, headquartered in St. Louis, is a pioneer in surgical robotics for minimally invasive endovascular intervention. It designs, manufactures and markets robotic magnetic navigation systems, including Genesis and GenesisX, the Odyssey information solution and proprietary disposables such as the MAGiC robotically navigated ablation catheter, …
Teva is headquartered in Tel Aviv and was founded in 1901. It pairs one of the world's largest generics businesses with a growing portfolio of innovative and biopharmaceutical medicines, and its specialty focus is on central nervous system, respiratory and oncology therapies, including Austedo, …
Tiziana is a clinical-stage biotechnology company founded in 1998 that develops immunomodulation therapies for neurodegenerative and neuroinflammatory diseases. Its lead asset, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody in Phase 2 development for non-active secondary progressive multiple sclerosis, multiple system atrophy, Alzheimer's …
uniQure is an Amsterdam-based gene therapy company founded in 1998 that develops single-treatment, potentially curative therapies for rare and devastating diseases using an AAV-based platform. Its commercial product is Hemgenix for hemophilia B, which is licensed to and marketed by CSL Behring. The pipeline …
UroGen, based in Princeton, New Jersey, is a commercial-stage biotechnology company that develops and commercializes non-surgical treatments for urothelial and specialty cancers, with operations in Israel. Its RTGel reverse-thermal hydrogel technology provides sustained local drug delivery and supports two FDA-approved products: Jelmyto for low-grade …
The REMS question traces to thalassemia. In those trials, 5 of 301 patients had liver injury, 2 of them serious. Mitapivat has been sold for thalassemia under theBrandAQVESME since late January, only under a REMS, according to published coverage. Agios reports no sickle cell …
The weak spot was joint replacement. Hip sales fell 1 percent while knee sales rose 1.1 percent, whereas Johnson & Johnson (NYSE:JNJ) reported knee growth of 2.5 percent and hip growth of 3.2 percent in the same period, according to published coverage. Lobo said …
The medical benefits ratio compares medical costs with premiums, so a 240 basis point rise means a larger share of each premium dollar went to care. The company cited Part D seasonality, the timing of clinical investments, elevated appeals and disputes, and higher costs …
Please wait processing your request...